Abstract
Shire is a leading specialty pharmaceutical company traditionally focused on
the treatment of attention deficit hyperactivity disorder (ADHD) and
gastrointestinal disorders. In 2005, Shire completed the acquisition of
Transkaryotic Therapies, broadening the company' s focus into the treatment of
genetic and renal diseases. In 2007, Shire purchased New River Pharmaceuticals
leading to a significant expansion of Shire' s ADHD product portfolio and
pipeline. The company' s headquarters are based in the UK, however, during its
20 years of operation, Shire has established a significant presence throughout
Europe and in the US.
In the last five years, Shire has spent over US$8 billion on acquisitions
which have seen the company considerably expand its global presence and areas
of interest. Most importantly, these acquisitions have added four key products
to a portfolio that was becoming dated and facing threats to its intellectual
property. The addition of Vyvanse (from New River Pharmaceuticals) will help
further cement the company' s position as a leader in the treatment of
attention deficit hyperactivity disorder (ADHD; traditionally Shire' s
strongest field). Meanwhile, the additions of Replagal and Elaprase (both from
Transkaryotic Therapeutics) have expanded Shire' s specialty centred business
into the treatment of genetic diseases. Furthermore, Dynepo (also from TKT)
has recently been launched and sees Shire enter the field of renal diseases.
During 2006, Shire reached a key settlement with Barr Pharmaceuticals. The two
companies had been involved in patent litigation over Adderall XR, Shire' s
top-selling product, which has patent protection until 2019. The agreement
between the two companies allows Barr to launch its generic Adderall XR
product ten years prior to patent expiry, however, it should prevent further
patent challenges and limit generic competition until 2019. A key component of
this agreement was the granting of a licence to Shire to begin developing
Duramed Pharmaceuticals' (a subsidiary of Barr) new oral contraceptive,
Seasonique, as well as five other products, which utilise Duramed' s
transvaginal ring technology. With this licence, Shire could begin to move
into yet another new key area of interest, women' s health, further expanding
what was previously a very limited product portfolio.
This new strategic analysis report Shire: Pipeline · Products ·
Performance · Potential, provides a complete and critical review of the
company and includes unique and independent assessments and forecasts of key
products. 4D Pharma reports are updated with the latest data on a continuing
basis and the full report is released quarterly. Once a year the report
undergoes a major review in line with the company' s year end. Buyers of the
print/pdf editions will receive the latest version and quarterly updated
reports for a year. Buyers of the web edition receive online access for one
year via an easy-to-use interface with fast navigation and a full text search
facility. All formats are the same price.
| 
View Cart
